Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Cerus Stock Down 1.0 %
CERS Stock traded down $0.05 during mid-day trading on Friday, reaching $5.20. 37,335 shares of the company traded hands, compared to its average volume of 1,523,998. The stock has a market cap of $920.87 million, a price-to-earnings ratio of -21.83 and a beta of 1.07. The company has a quick ratio of 1.73, a current ratio of 2.08 and a debt-to-equity ratio of 0.53. Cerus has a fifty-two week low of $4.34 and a fifty-two week high of $8.06. The firm's 50 day moving average price is $5.34 and its 200 day moving average price is $5.25.
Insider Buying and Selling at Cerus
In other Cerus news, insider Richard J. Benjamin sold 10,000 shares of Cerus stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $5.12, for a total transaction of $51,200.00. Following the completion of the transaction, the insider now owns 172,665 shares in the company, valued at approximately $884,044.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 7.33% of the company's stock.